A recent case series shows that clozapine can help soldiers with severe, treatment-resistant post-traumatic stress disorder successfully return to work and family life while significantly reducing aggression and suicidality. This atypical antipsychotic offers a promising new path for patients with combat-related trauma who have failed standard therapies. Combat-induced trauma notoriously produces highly chronic, disabling trajectories of post-traumatic stress disorder (PTSD) that show extreme resistance to first-line pharmacotherapies and trauma-focused psychotherapies. Exploring off-label clozapine in these refractory, non-psychotic cohorts offers a promising pathway to address profound functional impairment and lower premature mortality risks. Clozapine for Post-traumatic Stress Disorder: Redefining Treatment Resistance in Soldiers Without Psychosis.